ATG-034 / Antengene - LARVOL DELTA

Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cells (SITC 2023) - "Conclusions Our data showed that ATG-034-S3 potentiates NK-mediated ADCC, macrophage-mediated ADCP, CD8+ T cell-cytotoxicity and reverses AML-mediated T cell suppress, enhancing anti-tumor immunity (figure 1G), and demonstrates potent in vivo anti-tumor efficacy. ATG-034-S3 may be a promising strategy for the treatment of monocytic M4/M5 AML and other LILRB4 positive hematologic malignancies."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • APOE • CD123 • CD33 • CD8 • IL3RA • LILRB4

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it has presented results from five programs by poster presentation...at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023)....ATG-034-S3 potentiates NK-mediated ADCC, macrophage-mediated ADCP, cytotoxicity of CD8+ T cells and reverses AML-mediated T cell suppression, thus enhancing anti-tumor immunity and demonstrating potent in vivo anti-tumor efficacy. ATG-034-S3 may be a promising strategy for the treatment of monocytic M4/M5 AML and other LILRB-positive hematological malignancies."

Preclinical • Hematological Malignancies

Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023....The presentations feature five Antengene's clinical and preclinical programs, including two clinical programs, the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101; two preclinical programs, the LILRB4 antagonist antibody ATG-034 and the GPRC5D/CD3 T-cell engager ATG-021; as well as the proprietary novel AnTenGager™ platform."

Clinical data • Preclinical

ATG-034, an LILRB4 antagonist antibody, reinvigorates dendritic cells and prevents tumor progression (AACR 2023) - "Our data show that ATG-034 reprograms tolDC, enhancing anti-tumor immunity, and demonstrates potent in vivo anti-tumor efficacy. Therefore, ATG-034 may be a promising strategy for the treatment of cancer."

IO biomarker • Lung Cancer • Oncology • Solid Tumor • CD86 • HLA-C • IFNG • IL2RA • MRC1 • TNFA

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting (PRNewswire) - "This preclinical study was designed to evaluate ATG-034, an antibody targeting LILRB4, as a potential immunotherapy....According to the data, ATG-034 demonstrated single-digit nanomolar affinity and blocked the interaction of LILRB4 with its target ligand, fibronectin and completely reversed fibronectin-mediated suppression of tolerized DC activation (TolDC), evidenced by increased TNF-a production....These results suggest that ATG-034 successfully reprogrammed tolerized DCs to an 'immunogenic' state, thereby enhancing anti-tumor immunity and demonstrating potent in vivo anti-tumor efficacy compared to a benchmarking compound."

Preclinical • Oncology • Solid Tumor